Sanofi
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SAN.PA | SANOFI.BO | BIIB | PFE | 0QYQ.IL | GLAXO.BO | |
|---|---|---|---|---|---|---|
| Market cap | 100.96B | 77.83B | 37.61B | 175.50B | 219.86B | 423.63B |
| P/E (TTM) | 24.4 | 21.4 | 110.2 | 44.0 | 40.6 | 44.4 |
| Forward P/E | 9.1 | 19.0 | 15.6 | 10.6 | — | 36.9 |
| Price/book | 1.4 | 9.4 | 2.0 | 2.1 | 10.4 | 24.8 |
| Dividend yield | 4.90% | 3.56% | — | 5.59% | 3.81% | 1.75% |
| 1-year change | −1.76% | −27.27% | +62.35% | +23.90% | +40.64% | +6.17% |
| Today | +0.20% | +0.11% | +2.22% | +2.63% | +2.59% | −1.26% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All SAN.PA news ›Sanofi (SNY) Q3 2026 Earnings Call Transcript
Dupixent sales surge 34.8% as Sanofi upgrades full-year guidance on portfolio momentum. Friday, Oct. 30, 2026 Either raise your hand in Zoom or submit your question using the Q&A feature. Now I hand you over to Belén. Overall, the…
More from 1 other outlet
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Sanofi is pursuing deals for late-stage and commercial medicines after delivering another beat-and-raise quarter that emphasized its reliance on Dupixent. “We are laser-focused on ensuring growth beyond Dupixent [loss of exclusivity],”…
Eyes on Sanofi more than ever
By raising its full-year guidance, Sanofi is sending a positive signal to the market. It still needs to follow that up with tangible results, which will not be easy. Published on 11/02/2026 at 03:20 am EST It is true that, like its peers,…
Sanofi raises full-year outlook again
Faglig rådgiver til ATMP Danmark Head of Clinical Operations Clinical Trial Program Lead Senior Specialist, Drug Product Head of Medical Affairs International Markets Global Regulatory Strategy Lead, Senior Director Senior Scientist /…
Sanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory season
Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in 10 provinces and one territory for the fall 2026-2027 respiratory season A protein-based, non-mRNA vaccine that has demonstrated high efficacy against symptomatic…
Regeneron's Sanofi Windfall Drives A 19.5% Beat, But The Retinal Franchise Is Still Treading Water
New Upgrade: Dedicated Screeners for Stocks & ETFs The call also flagged several items unlikely to repeat: On a GAAP basis, EPS rose a more muted 35% to $18.45. The main drag was much lower gains on securities, which fell to $60 million…
Polycystic Kidney Disease Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma
Albany New York October 28 2026 As per DelveInsight s assessment globally Polycystic Kidney Disease pipeline constitutes 8 key companies continuously working towards developing 10 Polycystic Kidney Disease treatment therapies analysis of…
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO). In a report released today, Sachin Jain from Bank of America Securities…
Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4
"We're pleased to report another quarter of strong performance, driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise." (CEO Leonard ... Earnings Call Insights: Regeneron…
Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study
Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The trial evaluates a coformulated Dupixent plus berahyaluronidase alfa injection versus standard Dupixent alone. The goal is to see if…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com29
- seekingalpha.com15
- markets.businessinsider.com6
- ir.recursion.com3
- statnews.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.